Johnson & Johnson’s vaccine requires only one shot and can be stored at regular fridge temperatures, giving it an operational advantage over the Pfizer and Moderna jabs
LONDON – The single-shot Johnson & Johnson vaccine is highly effective in preventing severe COVID-19, including newer variants, according to documents released by the US Food and Drug Administration on Wednesday.
The news came as the regulator was set to convene an independent panel Friday that will likely vote to authorize the vaccine, making it the third available in the country hit hardest by the coronavirus pandemic.
In large clinical trials, the J&J vaccine’s efficacy against severe disease was 85.9 percent in the United States, 81.7 percent in South Africa, and 87.6 percent in Brazil.
For more on this story, visit eNCA